[go: up one dir, main page]

MX2023001678A - Metodos para tratar esclerosis multiple con ocrelizumab. - Google Patents

Metodos para tratar esclerosis multiple con ocrelizumab.

Info

Publication number
MX2023001678A
MX2023001678A MX2023001678A MX2023001678A MX2023001678A MX 2023001678 A MX2023001678 A MX 2023001678A MX 2023001678 A MX2023001678 A MX 2023001678A MX 2023001678 A MX2023001678 A MX 2023001678A MX 2023001678 A MX2023001678 A MX 2023001678A
Authority
MX
Mexico
Prior art keywords
ocrelizumab
multiple sclerosis
treating multiple
methods
grams
Prior art date
Application number
MX2023001678A
Other languages
English (en)
Inventor
Marianna Manfrini
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2023001678A publication Critical patent/MX2023001678A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Soy Sauces And Products Related Thereto (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a métodos para tratar esclerosis múltiple (MS) en un paciente mediante el uso del anticuerpo anti-CD20 ocrelizumab, y a un artículo de elaboración con instrucciones para tal uso. En particular, se refiere a un régimen de dosis de ocrelizumab en donde la dosis inicial y la segunda son de 1.2 gramos para pacientes de menos de 75 kg de peso o de 1.8 gramos para pacientes de 75 kg o más en un intervalo de alrededor de 6 meses.
MX2023001678A 2020-08-14 2021-08-12 Metodos para tratar esclerosis multiple con ocrelizumab. MX2023001678A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063066077P 2020-08-14 2020-08-14
US202063072673P 2020-08-31 2020-08-31
PCT/US2021/045792 WO2022036129A1 (en) 2020-08-14 2021-08-12 Methods for treating multiple sclerosis with ocrelizumab

Publications (1)

Publication Number Publication Date
MX2023001678A true MX2023001678A (es) 2023-02-22

Family

ID=77911120

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001678A MX2023001678A (es) 2020-08-14 2021-08-12 Metodos para tratar esclerosis multiple con ocrelizumab.

Country Status (10)

Country Link
US (2) US20220064320A1 (es)
EP (1) EP4196223A1 (es)
JP (1) JP2023537751A (es)
KR (1) KR20230048422A (es)
CN (1) CN116322765A (es)
AU (1) AU2021324842A1 (es)
CA (1) CA3190803A1 (es)
IL (1) IL300415A (es)
MX (1) MX2023001678A (es)
WO (1) WO2022036129A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024163542A2 (en) 2023-02-01 2024-08-08 Principia Biopharma Inc. Methods of diagnosing and treating multiple sclerosis
US20250179207A1 (en) * 2023-11-30 2025-06-05 Genzyme Corporation Methods for treating digitally-identified cd20-related disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
EP2325205A3 (en) 2000-12-28 2011-10-12 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
AR042485A1 (es) 2002-12-16 2005-06-22 Genentech Inc Anticuerpo humanizado que se une al cd20 humano
AU2005249566B2 (en) * 2004-06-04 2010-11-11 Genentech, Inc. Method for treating multiple sclerosis
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TW201438738A (zh) * 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
HUE069935T2 (hu) * 2015-10-06 2025-04-28 Hoffmann La Roche Módszer szklerózis multiplex kezelésére

Also Published As

Publication number Publication date
AU2021324842A1 (en) 2023-03-02
KR20230048422A (ko) 2023-04-11
US20220064320A1 (en) 2022-03-03
CA3190803A1 (en) 2022-02-17
IL300415A (en) 2023-04-01
CN116322765A (zh) 2023-06-23
EP4196223A1 (en) 2023-06-21
WO2022036129A1 (en) 2022-02-17
US20230322942A1 (en) 2023-10-12
JP2023537751A (ja) 2023-09-05

Similar Documents

Publication Publication Date Title
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2023001678A (es) Metodos para tratar esclerosis multiple con ocrelizumab.
AR050418A1 (es) Dosificacion fija de anticuerpos her
SG165344A1 (en) Method for treating vasculitis
TN2022000113A1 (en) Dosing regimen for anti-dll3 agents
BR112021022503A2 (pt) Métodos de administração de anticorpo anti-cd38 para tratar mieloma múltiplo
JOP20200014A1 (ar) توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2022014856A (es) Derivado de anticuerpo anti-nr1 humano.
MX2024007749A (es) Formulaciones clinicas de anticuerpos anti-tigit.
MX2022005628A (es) Regimen de dosificacion para agentes anti-bcma.
BRPI0716929A8 (pt) tratamento de esclerose múltipla com campath-1h
MX2022003010A (es) Tratamiento de la emr mediante cambio de terapia.
MX2022013923A (es) Metodos para tratar la enfermedad de crohn con el anticuerpo especifico anti-il23.
MX2025000682A (es) Composicion farmaceutica de anticuerpo anti-cd20 y uso de la misma
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
MX2022003266A (es) Dosis para anticuerpos anti-triptasa.
MX2024008330A (es) Combinacion de obicetrapib e inhibidor de sglt2
Franklin et al. Clinical studies with cortisone by mouth, cortisone by injection, and ACTH in the treatment of asthma
PE20240777A1 (es) Proteinas actrii y usos de las mismas
Lee et al. Paroxysmal autonomic instability with dystonia managed using chemodenervation including alcohol neurolysis and botulinum toxin type a injection: a case report
NZ781127A (en) Mirikizumab for use in a method of treating crohn’s disease
MX2023011047A (es) Dc009 para el tratamiento de accidente cerebro-vascular isquemico agudo.